Inclusion Criteria

          -  Disease Characteristics - Breast Cancer (Part 1A, Part 1B and Part 1C)

          -  Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2
             Negative (HER2-) breast cancer (2L + with prior CDK 4/6) locally advance or metastatic
             breast cancer. Participants should have received at least 1 line of SOC, including
             CDK4/6 inhibitor therapy, or at least 1 line of anti-endocrine therapy in countries
             without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease

          -  Part 1A only: Refractory HR-positive (HR+), Human Epidermal Growth Factor Receptor 2
             Positive (HER2+) breast cancer

          -  Evaluable lesion (including skin or bone lesion only)

          -  Disease Characteristics - Part 1A: Tumors other than BC

          -  Participants with advanced or metastatic disease

          -  Participants with histological or cytological diagnosis of adenocarcinoma of NSCLC,
             prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1
             amplification according to local standard tests, that is resistant to at least 2 lines
             of standard systemic therapy for advanced or recurrent disease or for which no
             standard therapy is available

          -  Participants must not be eligible to undergo therapy with curative intent (surgery or
             radiation therapy with or without chemotherapy

        General Inclusion Criteria

          -  All participants must be refractory to or intolerant of existing therapies known to
             provide clinical benefit for their condition.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

          -  Adequate renal, liver, and bone marrow function

        Exclusion Criteria:

          -  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
             carcinomatous meningitis, or leptomeningeal disease

          -  Other active malignancy within 3 years prior to randomization, except for adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ

          -  Major surgery or radiation within 4 weeks prior to study intervention

          -  Last anti-cancer treatment within 2 weeks prior to study intervention

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study entry

          -  Pregnant or breastfeeding female participant

          -  Active inflammatory gastrointestinal (GI) disease, known diverticular disease or
             previous gastric resection or lap band surgery including impairment of
             gastrointestinal function or GI disease